CMB International: Maintains INNOVENT BIO's "Buy" rating, with the Target Price raised to 57.67 HKD.

CMB International has released a research report stating that it maintains a "Buy" rating for INNOVENT BIO (01801), being bullish on the global potential of INNOVENT's Innovative Drugs pipeline, and has raised the target price to HKD 57.67 (previous value: HKD 55.21; WACC: 9.5%, perpetual growth rate: 3.5%). The company has licensed the global rights of the new DLL3ADC (IBI3009) to Roche, receiving an upfront payment of USD 80 million and up to USD 1 billion in milestone payments and sales sharing. The drug is expected to receive IND approval for global Phase 1 research in December 2024. Regarding the DLL3 target, besides

Sina Hong Kong StocksJan 3 03:36 ET

Risks Still Elevated At These Prices As Legend Biotech Corporation (NASDAQ:LEGN) Shares Dive 26%

Simply Wall StJan 2 07:34 ET

Karyopharm Tapped Lori Macomber Of Legend Biotech As CFO, Effective January 3

BenzingaJan 2 07:06 ET

Breaking Down Legend Biotech: 9 Analysts Share Their Views

BenzingaDec 30, 2024 13:00 ET

Legend Biotech Analyst Ratings

BenzingaDec 30, 2024 12:19 ET · Ratings

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and NewAmsterdam Pharma Company (NAMS)

TipRanksDec 30, 2024 06:40 ET · Ratings